Parkinson's Disease
Conditions
Keywords
Parkinson's disease, dyskinesia, levetiracetam, keppra
Brief summary
The primary purpose of this study is to characterize the acute anti-dyskinetic properties of intravenous levetiracetam in Parkinson's disease patients who have been optimized on antiparkinsonian medication. The secondary objective is to study the effect of intravenous LEV on additional motor and cognitive symptoms of PD.
Interventions
DRUGlevetiracetam
100 - 500mg IV q 15 min
DRUGPlacebo
Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min
Sponsors
University of South Florida
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Outpatients with idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnosis Criteria. 2. Age 30 years to 80 years. 3. Dyskinesias with a minimum severity equal to a rating of 10 or higher on the AIMS rating scale at baseline. 4. Dyskinesias at least moderately disabling (historical information from item 33 of UPDRS). 5. Stable dose of antiparkinsonian medication 4 weeks prior to study entry. 6. Women of child-bearing potential must use a reliable method of contraception and must be willing to perform a pregnancy test paid for and provided by Dr. Zesiewicz and the USF Medical Clinic. There must be a negative result before entry into the study.
Exclusion criteria
1. Any illness that in the investigator's opinion preclude participation in this study. This includes patients with unstable disease and those PD patients who can not tolerate IV infusion. 2. Pregnant or lactating women. Pregnancy will not be allowed whether as a pre-existing condition or a positive result on the pregnancy test in the screening process. Lactation includes any woman wanting to participate who is currently breast-feeding. 3. Patients may not be dual enrolled to another research study requiring the patient to sign informed consent. 4. Dementia or other psychiatric illness that prevents the patient from giving informed consent (Mini Mental Status Exam score of less than 20). 5. Legal incapacity or limited legal capacity. 6. Presence of severe renal disease (BUN 50% greater than normal). Patients must have evidence from their PCP or Urologists of normal PSA and urodynamic tests within the last 12 months; patients with BUN 50% greater than normal (5 to 20 mg/ d L) or creatinine 50% greater than normal (0 .7 and 1.4 mg/ d L) will be excluded. Labs will be requested from PCP. 7. Concomitant or prior therapy with the following treatments: neuroleptics, metoclopramide, domperidone (in doses \>60mg/day), azole antifungals (e.g. ketoonazole), etomidate, ciprofloxacin, fluvoxamine, cimetidine, fludrocortizone, encainide, flecainide, mexiletine, propafenone, guanoxane, maprotiline, antidepressants on doses higher than the maximum approved daily dose for outpatients, intermittent therapy with oral corticoids. 8. Patients who are not fluent in English.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Abnormal Involuntary Movements Scale (AIMS) | 15 minutes |
Secondary
| Measure | Time frame |
|---|---|
| Rush Dyskinesia Rating Scale | 15 minutes |
Countries
United States
Outcome results
None listed